SCHEMBL7229897

SCHEMBL7229897

C/N=C/c1ccc2c(c1)OCCO2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
HPGD P15428 4/20 0.58
KDM4E B2RXH2 5/20 0.57
HSD17B10 Q99714 1/20 0.57
KMT2A Q03164 5/20 0.55
ATM Q13315 2/20 0.55
RAB9A P51151 7/20 0.54
GAA P10253 4/20 0.54
HTT P42858 2/20 0.54
MAPT P10636 6/20 0.51
SMN1; SMN2 Q16637 6/20 0.50
MEN1 O00255 4/20 0.50
NPC1 O15118 4/20 0.50
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 2/20 0.48
CYP3A4 P08684 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4447859 0.89 CYP3A4 (0.59) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL3154846 0.89 CYP3A4 (0.59) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL5563991 0.81 RAB9A (0.58) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL5563987 0.81 RAB9A (0.58) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL7492 0.78 ATM (0.55) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL11790505 0.77 RAB9A (0.54) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL11790484 0.77 RAB9A (0.54) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL19215448 0.76 ALDH1A1 (0.57) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL15748984 0.74 RAB9A (0.48) ALDH1A1HPGDKDM4EHSD17B10KMT2A
SCHEMBL15803748 0.74 ALDH1A1 (0.50) ALDH1A1HPGDKDM4EHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6509344-B1 A method for treating a patient having cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 1, whereupon said patient is treated for cancer, and wherein the cancer is THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2003-01-21 US disclosed